GlassScriptPhysician profile
David S Oyer
NPI 1134226467
$101,262.58
in general payments reported to CMS, 2019-2025
18 companies · $567 in 2025
The $567 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $16K · 2021: $11K · 2022: $16K · 2023: $513 · 2024: $886 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355 · Education: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.41 |
| Education | $611.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $66,584.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $32,351.98 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,242.28 | 2021-2025 | |
| Mannkind Corporation | $294.25 | 2019-2025 | Afrezza |
| Corcept Therapeutics | $139.18 | 2024 | Korlym |
| Regeneron Pharmaceuticals, INC. | $135.00 | 2019 | |
| Senseonics, Incorporated | $124.00 | 2019 | |
| Exact Sciences Corporation | $78.71 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $53.08 | 2022-2024 | |
| Amgen INC. | $50.78 | 2019-2025 | Repatha, Otezla |
| Insulet Corporation | $47.04 | 2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $32.82 | 2025 | Strensiq |
| Glaxosmithkline, LLC. | $25.00 | 2023 | Shingrix |
| Xeris Pharmaceuticals, INC. | $24.93 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $21.52 | 2023 | Freestyle Libre 3 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.00 | 2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.26 | 2022 | |
| Dexcom, INC. | $18.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.